Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- XTLB.TA
- Price
- 4.40
- Stock movement up
- +0.20 (4.76%)
- Company name
- XTL Biopharmaceuticals Ltd
- Exchange
- (TA ,
- Currency
- ILA )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.40B
- Ent value
- 2.40B
- Price/Sales
- -
- Price/Book
- 886.35
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -56.44%
- 3 year return
- -15.14%
- 5 year return
- -2.52%
- 10 year return
- -19.77%
Last updated: 2025-04-12
DIVIDENDS
XTLB.TA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 886.35 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 544.91M |
| EPS (TTM) | -0.00 |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -689.00K |
| Net income (TTM) | -378.00K |
| EPS (TTM) | -0.00 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.07M |
| Net receivables | 0.00 |
| Total current assets | 2.55M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 2.93M |
| Accounts payable | 223.00K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 223.00K |
| Total liabilities | 223.00K |
| Shareholder's equity | 2.71M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 0.00 |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | 0.00 |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -13.97% |
| Return on Assets | -12.91% |
| Return on Invested Capital | -13.97% |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.40 |
| Daily high | 4.50 |
| Daily low | 4.30 |
| Daily Volume | 163K |
| All-time high | 2569.50 |
| 1y analyst estimate | - |
| Beta | 1.00 |
| EPS (TTM) | -0.00 |
| Dividend per share | - |
| Ex-div date | 15 Mar 2022 |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| XTLB.TA | S&P500 | |
| Current price drop from All-time high | -99.83% | -14.41% |
| Highest price drop | -99.88% | -56.47% |
| Date of highest drop | 7 Aug 2023 | 9 Mar 2009 |
| Avg drop from high | -92.70% | -11.07% |
| Avg time to new high | 404 days | 12 days |
| Max time to new high | 4810 days | 1805 days |
COMPANY DETAILS
Marketcap
2.40B
Marketcap category
Mid-cap
Description
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Israel
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”) announ...
April 7, 2025
expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Completed a Private Placement of $1.5 M...
August 14, 2024
expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Place...
June 5, 2024